Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
Acta Diabetologica, 2020 Aims SARS–CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19.
S. B. Solerte +3 more
semanticscholar +1 more source
Cardiovascular Diabetology, 2012 Background Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially
Klempfner Robert +4 more
doaj +1 more source
Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin [PDF]
Ķazaķstannyṇ Klinikalyķ Medicinasy, 2018 Aim: A study was conducted to assess the clinical and economic effectiveness of vildagliptin in adults with type 2 diabetes mellitus (T2DM) with poor glycemic control against the metformin monotherapy.
Alima Almadiyeva +3 more
doaj +1 more source
[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Leprdb/db type 2 diabetic mice [PDF]
, 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give ...
Akhter, Farjana +9 more
core +2 more sources
Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins.
Journal of food biochemistry, 2019 Dipeptidyl peptidase IV (DPP-IV) is involved in incretin hormone processing and therefore plays a key role in glycemic regulation. This review summarizes the latest developments in food protein-derived DPP-IV inhibitory peptides. The in silico approaches
A. Nongonierma, R. Fitzgerald
semanticscholar +1 more source
Diabetes, obesity and metabolism, 2020 We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without
K. Birkeland +14 more
semanticscholar +1 more source
miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease
JACC: Basic to Translational Science, 2019 Summary: As a consequence of the success of present-day cancer treatment, radiotherapy-induced vascular disease is emerging. This disease is caused by chronic inflammatory activation and is likely orchestrated in part by microRNAs.
Suzanne M. Eken, MD, PhD +14 more
doaj +1 more source
Dipeptidyl Peptidase IV as a Muscle Myokine
Frontiers in Physiology, 2020 Dipeptidyl peptidase IV (DPP-IV) is a unique serine protease that exists in a membrane bound state and in a soluble state in most tissues in the body.
Heidi A. Kluess
doaj +1 more source
Journal of Diabetes Investigation, 2022 Aims/Introduction The union of dipeptidyl peptidase‐4 inhibitors and insulin in patients with type 2 diabetes and chronic kidney disease provides satisfactory glucose management without increasing adverse events (AEs).
Xianling Zhou +4 more
doaj +1 more source
Family C1 cysteine proteases: Biological diversity or redundancy? [PDF]
, 2003 Recent progress in the identification and partial characterization of novel genes encoding cysteine proteases of the papain family has considerably increased our knowledge of this family of enzymes.
Brömme D. +4 more
core +1 more source